| INTRODUCTION
Diabetes mellitus is a risk factor for the development of chronic kidney disease (CKD) and cardiovascular disease. 1, 2 Endothelial dysfunction represents the earliest change in the process of atherosclerosis, which is a major complication and the factor most correlated with mortality in CKD, 3 and is known to be a powerful surrogate marker of cardiovascular events. 4 Recently, endothelial function as evaluated by flowmediated dilation (FMD) has been recognized as an independent predictor of future cardiovascular events in clinical settings.
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Erythropoietin (EPO) is a hematopoietic hormone, and its receptor is widely distributed in both hematopoietic cells and nonhematopoietic cells, including endothelial and smooth muscle cells. 6 Epoetin beta pegol, commonly known as continuous erythropoietin receptor activator (C.E.R.A.), is a unique erythropoiesis-stimulating agent (ESA) for the treatment of anemia in patients with CKD. C.E.R.A. has been modified by integration of methoxypolyethylene glycol into the molecule, endowing it with a long half-life and slow clearance rate. 7 A previous report demonstrated that C.E.R.A. prevented the reduction of FMD in CKD rats. 8 However, there is as yet no evidence about the effect of C.E.R.A. on diabetes-related reduction in FMD.
There are several diabetic model rats, such as Goto-Kakizaki rats, Otsuka Long-Evans Tokushima Fatty rats, and Zucker Diabetic Fatty rats. These rats all develop obesity, hyperinsulinemia, and hypertension.
The Spontaneously Diabetic Torii (SDT) rat is also a diabetic nephropathy model, but does not exhibit obesity, hyperinsulinemia, or hypertension. 9 Therefore, SDT rats enable us to evaluate hyperglycemiainduced endothelial dysfunction without those other influences. 10 The aim of this study was to examine the effect of C.E.R.A. on FMD in SDT rats. In addition, we also investigated the influence of Hb levels on FMD.
| MATERIALS AND METHODS

| Animals
Male SDT rats (22 weeks old; CLEA Japan, Inc., Tokyo, Japan) were used as nonobese type 2 diabetic rats. Male Sprague-Dawley rats (SD, 22 weeks old; CLEA Japan, Inc.) were used as age-matched control rats because SDT rat is an inbred strain of SD rat. All rats were fed ordinary laboratory chow and allowed free access to water under a 
| Measurement of FMD
Flow-mediated dilation was measured in rats as described previously. 17, 18 Briefly, rats were anesthetized with thiobutabarbital FMD was taken to be the peak change in femoral arterial diameter after reperfusion, as the clinical guidelines for assessment of FMD define the peak change in brachial arterial diameter as an endothelial function to be that which occurs approximately 1 minute after reperfusion. 19 After measuring FMD, endothelium-independent vasodilation was also evaluated by monitoring the vasodilation induced by intravenous injection of nitroglycerin (NTG, 5 μg/kg). Hb levels and Hct were assessed using an automated hematology analyzer (XT-2000iV, Sysmex, Hyogo, Japan).
| Measurement of plasma and urine parameters
| Western blotting analysis
Rats were euthanized by exsanguination under anesthesia with thiobutabarbital, and femoral arteries were harvested and frozen in liquid N 2
immediately after isolation and stored in a freezer at −80°C. To investigate the state of eNOS uncoupling, low-temperature SDS-PAGE was performed. 20 Briefly, protein extracts were mixed with sample buffer (without β-mercaptoethanol), and nonboiled samples were separated on SDS-polyacrylamide gel on ice. Immunoblotting was performed with anti-eNOS antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or with antinitrotyrosine antibodies (Santa Cruz Biotechnology).
| Statistical analyses
All data are expressed as mean±SEM. The n values refer to the number of individual animals in each group on which experiments were performed. The statistical significance of differences was determined using unpaired t-test or Dunnett's test. Test of no correlation was also performed. Probability values of less than .05 were considered significant. Statistical analyses were performed using JMP version 11.2.1 software (SAS Institute, Cary, NC, USA).
| RESULTS
| Endothelial function before C.E.R.A. treatment in SDT rats
Before the start of C.E.R.A. treatment, the blood glucose level of SDT Figure 1A ,B). After the measurement of FMD,
we also assessed the vascular smooth muscle function which could influence the vasodilatory potency. NTG-induced vasodilation was rather increased in SDT rats ( Figure 1C ). Figure 2A ,B). C.E.R.A. did not affect the endothelium-independent vasodilation by NTG injection ( Figure 2C ).
| Effects of repeated administration of C.E.R.A. on FMD in SDT rats
To evaluate the state of eNOS uncoupling, which is a cause of endothelial dysfunction, we detected eNOS dimer and eNOS monomer in femoral arteries. The eNOS dimer/monomer ratio was lower in vehicle-treated SDT rats, and C.E.R.A. dose-dependently increased the eNOS dimer/monomer ratio ( Figure 3A ), which showed a positive correlation with FMD in SDT rats ( Figure 3D ). Total eNOS expression was upregulated in vehicle-treated SDT rat, and C.E.R.A. showed no influence on it ( Figure 3B ). Because oxidative stress is a cause of eNOS uncoupling, we evaluated nitrotyrosine accumulation, which is a marker of peroxynitrite. Nitrotyrosine accumulation was increased in femoral arteries of SDT rats, and repeated treatment with C.E.R.A. showed a tendency, but not significantly, to reduce the increase of it ( Figure 3C ).
On the other hand, there was no correlation between FMD and Hb or Hct in SDT rats ( Figure 3E,F) , although C.E.R.A. (1.2 μg/kg) increased Hb and Hct (Table 1) . Baseline femoral artery diameter at the measurement of FMD in vehicle-treated SDT rats was larger than in SD rats, and it was reduced by C.E.R.A. treatment (Table 1) . However, there was no correlation between FMD and baseline diameter of femoral artery ( Figure 3G ). C.E.R.A. showed no influence on blood glucose, kidney function (urinary protein, BUN), or body weight (Table 1) . 
| Effects of single treatment with C.E.R.A. on FMD in SDT rats
To examine whether Hb upregulation itself could increase FMD, we measured FMD 1 week after single administration of C.E.R.A. 
| DISCUSSION
In the present study, C.E.R.A. treatment was started after onset of endothelial dysfunction in SDT rats. Repeated treatment with C.E.R.A.
improved FMD and the eNOS dimer/monomer ratio in SDT rats.
Furthermore, FMD showed a positive correlation with eNOS dimer/ monomer ratio but not with Hb or Hct. In addition, single administra- Cu/Zn-SOD and heme oxygenase-1 expression via PI3K/Akt pathway. 13 EPO could also induce the expression of SOCS-1, which reduces NADPH oxidase activity, depending on STAT5 signaling. 13, 30 Our previous report showed that repeated treatment with C.E.R.A. reduced oxidative stress in the femoral arteries of 5/6 nephrectomized rats. 8 In addition, it was also reported that treatment with C.E.R.A. could ameliorate oxidative stress with enhancing the antioxidant defense system and reducing ROS production in patients with CKD. 31 In the present study, repeated treatment with C.E.R.A. showed a nonsignificant In conclusion, we demonstrated that repeated administration of C.E.R.A. improved FMD in SDT rats even after onset of endothelial dysfunction. In addition, FMD was correlated with eNOS dimer/monomer ratio but not with Hb and Hct levels. Our results are expected to clarify the effect of C.E.R.A. on endothelial or cardiovascular function in patients with diabetic nephropathy.
